证券简称：诚意药业 证券代码：603811 浙江诚意药业股份有限公司 2025 年员工持股计划 （草案） 二〇二五年七月 浙江诚意药业股份有限公司 2025 年员工持股计划（草案） 声明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误 导性陈述或重大遗漏，并对其真实性、准确性、完整性承担法律责任。 1 浙江诚意药业股份有限公司 2025 年员工持股计划（草案） 风险提示 一、本员工持股计划须经公司股东会审议通过后方可实施，本员工持股计划 能否获得公司股东会批准，存在不确定性。 二、有关本员工持股计划的具体资金来源、出资金额、实施方案等属初步结 果，能否完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则，若员工认购资金较低时， 本员工持股计划存在无法成立的风险；若员工认购资金不足，本员工持股计划存 在低于预计规模的风险。 四、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩预测， 亦不构成业绩承诺。 五、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 2 浙江诚意药业股份有限公司 2025 年员工持股计划（草案） 特别提示 一、浙江 ...

证券简称：诚意药业 证券代码：603811 浙江诚意药业股份有限公司 2025 年员工持股计划 （草案）摘要 二〇二五年七月 浙江诚意药业股份有限公司 2025 年员工持股计划（草案）摘要 声明 本公司及董事会全体成员保证本员工持股计划及其摘要不存在虚假记载、误 导性陈述或重大遗漏，并对其真实性、准确性、完整性承担法律责任。 1 浙江诚意药业股份有限公司 2025 年员工持股计划（草案）摘要 风险提示 一、本员工持股计划须经公司股东会审议通过后方可实施，本员工持股计划 能否获得公司股东会批准，存在不确定性。 二、有关本员工持股计划的具体资金来源、出资金额、实施方案等属初步结 果，能否完成实施，存在不确定性。 三、员工遵循依法合规、自愿参与、风险自担原则，若员工认购资金较低时， 本员工持股计划存在无法成立的风险；若员工认购资金不足，本员工持股计划存 在低于预计规模的风险。 四、本员工持股计划中有关公司业绩考核指标的描述不代表公司的业绩预测， 亦不构成业绩承诺。 五、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 2 浙江诚意药业股份有限公司 2025 年员工持股计划（草案）摘要 特 ...

New Stock Listings - Yitang Co., Ltd. (688729) listed at an issue price of 8.45 on July 8, 2025[1] - Jichuan Pharmaceutical (600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10 to July 9, 2025[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 8 trading days remaining until the last trading day[1] - Hengli Tui (000622) has 5 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has 4 trading days remaining until the last trading day[1] Market Volatility - North China Long Dragon (301357) reported severe abnormal fluctuations[1] - Multiple stocks including ST Zhengping (603843) and Hunan Tianyan (600698) have reported abnormal fluctuations[3]

New Stock Issuance - Huadian New Energy (证券代码: 730930) issued shares at a price of 3.18 on July 7, 2025[1] - Jichuan Pharmaceutical (证券代码: 600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (证券代码: 603389) has a tender offer period from June 10 to July 9, 2025[1] Trading Alerts - The last trading day for TSM Jinguang (证券代码: 600190) is in 9 trading days[1] - The last trading day for TSM Jinyou (证券代码: 600462) is in 5 trading days[1] - The last trading day for TSM Gongzhi (证券代码: 000584) is in 3 trading days[1] Abnormal Fluctuations - Northern Long (证券代码: 301357) is experiencing severe abnormal fluctuations[1] - ST Dongjing (证券代码: 002199) reported abnormal fluctuations[3] - ST Yunchuang (证券代码: 835305) reported abnormal fluctuations on July 4, 2025[3]

浙江诚意药业股份有限公司 公司股票于 2025 年 7 月 1 日、7 月 2 日、7 月 3 日连续 3 个交易日内日收盘 价格涨幅偏离值累计达到 20%，根据《上海证券交易所交易规则》的有关规定， 属于股票交易异常波动情形。 证券代码：603811 证券简称： 诚意药业 公告编号：2025-033 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江诚意药业股份有限公司（以下简称"公司"）股票交易于 2025 年 7 月 1 日、7 月 2 日、7 月 3 日连续 3 个交易日内日收盘价格涨幅偏离值累计达到 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情 形。 经公司自查，并书面问询公司控股股东、实际控制人，截至本公告披露 日，公司及控股股东、实际控制人不存在应披露而未披露的重大信息。 一、股票交易异常波动的具体情况 公司股票连续 3 个交易日内（2025 年 7 月 1 日、7 月 2 日、7 月 3 日）日收 盘价格涨幅偏离值累计超过 20%，属于股票交易 ...

Core Viewpoint - The short-term sentiment in the market has improved, with a significant number of stocks reaching their upper limit, indicating a potential recovery in investor confidence [1] Group 1: Market Performance - A total of 61 stocks hit the daily limit, with 14 stocks classified as consecutive limit-up stocks, and 5 of these achieved three consecutive limit-ups or more [1] - The upgrade rate for consecutive limit-up stocks was 41.67%, excluding ST and delisted stocks [1] - Over 3,200 stocks in the market experienced an increase, reflecting a broad-based rally [1] Group 2: Notable Stocks - Chengbang Co. achieved a limit-up, marking its sixth consecutive limit-up [1] - Dazhongnan showcased a "ground-to-sky" performance with 8 limit-ups in 6 days [1] - Haoshanghao reached a historical high with 5 limit-ups over 7 days [1] Group 3: Sector Performance - The innovative drug sector led the market gains, with notable performances from companies like Innovent Biologics, which saw a rise of over 9% in Hong Kong [1] - In the A-share market, Selin Medical achieved three consecutive limit-ups, while Chengyi Pharmaceutical and Weiming Pharmaceutical recorded two and three limit-ups, respectively [1] - The PCB sector also showed strength, with Shenghong Technology increasing over 6%, surpassing a market capitalization of 120 billion, and Pengding Holdings hitting the limit-up [1]

Group 1: Industry Overview - The Chinese government is actively promoting the development of the marine economy, with "deep-sea technology" becoming a key focus area in national policies [2][3] - The marine economy is expected to grow significantly, with projections indicating that by 2025, the marine production value could exceed 13 trillion yuan, with deep-sea technology-related industries accounting for over 25% of this total [4] Group 2: Company Developments - Hengtong Optic-Electric plans to expand its marine communication industry chain, focusing on the development and industrialization of products related to offshore oil and gas, underwater special cables, and marine equipment [1][5] - Zhongke Haixun is leveraging its advantages in sonar equipment, promoting its HX-A200 core processing chip specifically designed for underwater acoustic equipment, with plans for mass orders by 2025 [1][6] - Qifan Cable has developed the capability to produce long-length submarine cables and has applied these products in offshore wind power projects, with ongoing investments in R&D to enhance competitiveness in high-performance cable manufacturing [1][6] - Chengyi Pharmaceutical is investing 670 million yuan in a marine biomedicine manufacturing project, focusing on the production of 1,000 tons of super fish oil EPA, aligning with national marine strategies [1][7]

证券代码：603811 证券简称：诚意药业 公告编号：2025-032 浙江诚意药业股份有限公司 关于以集中竞价方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/1 | | --- | --- | | 回购方案实施期限 | 2024.9.30~2025.9.29 | | 预计回购金额 | 5,000万元~10,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 961.8796万股 | | 累计已回购股数占总股本比例 | 2.94% | | 累计已回购金额 | 7,639.7832万元 | | 实际回购价格区间 | 7.25元/股~8.36元/股 | 一、回购股份的基本情况 浙江诚意药业股份有限公司（以下简称"公司"）于 2024 年 9 月 29 日召开了 第四届董事会第十一次会议，审议通过了《关于以集中竞价交易 ...

Group 1 - The A-share market saw active performance in marine biopharmaceutical concept stocks, with companies like Chengyi Pharmaceutical, Haiwang Biological, and Dongfang Ocean hitting the daily limit up [1] - The Central Financial Committee emphasized the promotion of a unified national market and the high-quality development of the marine economy [1] - Chengyi Pharmaceutical, as the first listed company in Zhejiang focusing on marine biopharmaceuticals, has a revenue share of nearly 70% from this sector [1] Group 2 - Chengyi Pharmaceutical is leveraging its core businesses of glucosamine and fish oil to establish a strong presence in the marine biopharmaceutical field [1] - The company's key product, hydrochloride glucosamine, is derived from chitin sourced from crab and shrimp shells, offering unique advantages such as being all-natural and additive-free [1] - Chengyi Pharmaceutical has developed a full-chain integration advantage in glucosamine products, from raw material extraction to production [1] Group 3 - Dongfang Ocean is also gaining market attention, focusing on marine seed breeding, aquatic product processing, and biotechnology [2] - The company has established a leading position in sea cucumber farming and fish seed breeding, collaborating with institutions like the Chinese Academy of Sciences and Ocean University of China [2] - Dongfang Ocean is advancing its health industry development by establishing platforms for immune technology, mass spectrometry, molecular technology, and third-party medical testing laboratories [2]

Group 1 - The Central Financial Committee's sixth meeting emphasizes the development of a national unified market and the high-quality development of the marine economy, highlighting the importance of marine economic growth for China's modernization [1] - The marine biomedicine sector is recognized as a significant area for development, with projections indicating that the market size in China will reach approximately 33.1 billion yuan in 2024, representing a 20% year-on-year growth [1] - Companies in the marine biomedicine industry, such as Sea King Biological (000078), Blue Ocean Biological (603739), and Chengyi Pharmaceutical (603811), are positioned to benefit from policy support and are undergoing value reassessment [1][2] Group 2 - Chengyi Pharmaceutical, as the first listed company in Zhejiang Province focused on marine biomedicine, has developed a strong presence in the sector, particularly with its core product, glucosamine hydrochloride, derived from natural sources like crab and shrimp shells [2] - The company has established a comprehensive supply chain from raw material extraction to drug formulation, enhancing its competitive edge in the marine biomedicine market [2] - Oriental Ocean is also gaining market attention, with its operations in marine seed breeding, aquatic product processing, and biotechnology, and has established collaborations with leading research institutions to enhance its research and development capabilities [3]